Sagimet Biosciences Inc. Series A Common Stock reports a Return on Equity (ROE) of -42.47%.

What is SGMT's dividend yield?

Sagimet Biosciences Inc. Series A Common Stock offers a dividend yield of 0.00%.

What is SGMT's Quality Score?

Our AI rates SGMT's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SGMT?

Our AI Timing Score for SGMT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SGMT belong to?

Sagimet Biosciences Inc. Series A Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Sagimet Biosciences Inc. Series A (SGMT) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

SGMT AI Analysis Summary

Our AI summary for SGMT: Sagimet Biosciences Inc. Series A Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -42.47%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SGMT

Sagimet Biosciences Inc. Series A Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 86

USD 7.99

0.84 (11.75%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-42.5%

ROE

-40.4%

ROA

0.00%

Div Yield

SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.99 Price 0.84 (11.75%) Day Change	NEWS SCORE: 86

SGMT, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	86
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	7.99
PBV / Sector	4.31 / 44,022.72
Earning Per Share	-0.79

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	7.33 M
Average 1W Daily Value	9.04 M

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	-1,393.80 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-40.38 / 185,260.96
ROA Average (%) / Sector	-46.76 / 36,684.70
ROA Change Average (%) / Sector	-5.97 / 422,221.66
ROE (%) / Sector	-42.47 / 243,762.23
ROE Average (%) / Sector	-26.37 / 48,758.47
ROE Change Average (%) / Sector	-60.68 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:50
Symbol	SGMT
Name	SAGIMET BIOSCIENCES INC. SERIES A COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	61.18 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	441.53 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 155 Bovet Road, San Mateo, CA, United States, 94402

Phone: 650 561 8600

Website: https://www.sagimet.com

Sector: Healthcare >> Biotechnology

Description: Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.